Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study.

被引：1

作者：

Dreyling, Martin H.

Leppa, Sirpa

Comeau, Terrance

Kosinova, Marina

Lenz, Georg

Nagler, Arnon

Heo, Dae Seog

Oh, Sung Yong

Huang, Liping

Wirtz, Oliver

Miriyala, Ashok

Garcia-Vargas, Jose E.

Childs, Barrett H.

Zinzani, Pier Luigi

机构：

[1] Klin Univ Munchen LMU, Medizin Klin & Poliklin 3, Munich, Germany

[2] Helsinki Univ Cent Hosp Canc Ctr, Helsinki, Finland

[3] St Johns Hosp, St John, NB, Canada

[4] Kemerovo Reg Reg Clin Hosp, Kemerovo, Russia

[5] Munster Univ Clin, Translat Oncol Med Clin, Munster, Germany

[6] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel

[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[8] Dong A Univ Coll Med, Dept Internal Med, Busan, South Korea

[9] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[10] Bayer AG, Pharmaceut Div, Wuppertal, Germany

[11] Univ Bologna, Inst Hematol L E A Seragnoli, Bologna, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.7570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7570

引用

页数：1

共 50 条

[21] RETREATMENT WITH BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL LYMPHOMA AND MANTLE CELL LYMPHOMA
Yamada, Toshiki
Nakamura, Nobuhiko
Kitagawa, Jun-ichi
Kanemura, Nobuhiro
Goto, Naoe
Kasahara, Senji
Goto, Hideko
Fukuno, Kenji
Hara, Takeshi
Tsurumi, Hisashi
ANNALS OF ONCOLOGY, 2014, 25
[22] Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma
Dreyling, Martin H.
Santoro, Armando
Leppa, Sirpa
Demeter, Judit
Follows, George
Lenz, Georg
Kim, Won Seog
Mollica, Luigina
Nagler, Arnon
Diong, Colin Phipps
Provencio, Mariano
Magagnoli, Massimo
Radinoff, Atanas
Munoz, Javier
Cao, Anjun
Hiemeyer, Florian
Odongo, Fatuma
Garcia-Vargas, Jose E.
Childs, Barrett H.
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma
Munakata, Wataru
Shirasugi, Yukari
Tobinai, Kensei
Onizuka, Makoto
Makita, Shinichi
Suzuki, Rikio
Maruyama, Dai
Kawai, Hidetsugu
Izutsu, Koji
Nakanishi, Tadashi
Shiba, Sari
Hojo, Seichiro
Ando, Kiyoshi
CANCER SCIENCE, 2021, 112 (03) : 1123 - 1131
[24] Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Dreyling, Martin
Santoro, Armando
Mollica, Luigina
Leppae, Sirpa
Follows, George
Lenz, Georg
Kim, Won Seog
Nagler, Arnon
Dimou, Maria
Demeter, Judit
Oezcan, Muhit
Kosinova, Marina
Bouabdallah, Krimo
Morschhauser, Franck
Stevens, Don A.
Trevarthen, David
Munoz, Javier
Rodrigues, Liana
Hiemeyer, Florian
Miriyala, Ashok
Garcia-Vargas, Jose
Childs, Barrett H.
Zinzani, Pier Luigi
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : 362 - 371
[25] Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma
Di Bella, Nicholas
Taetle, Raymond
Kolibaba, Kathryn S.
Boyd, Thomas E.
Raju, Robert N.
Barrera, David N.
Cochran, Ernest
Dien, Philip
Hakimian, David
Lyons, Roger M.
Schlegel, Peter J.
Vukelja, Svetislava J.
Boston, Julie
Boehm, Kristi A.
Wang, Yunfei
Asmar, Lina
BLOOD, 2008, 112 (11) : 558 - 558
[26] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
Bennani, N. Nora
Atherton, Pamela
Steinert, Kimberly O.
Rimsza, Lisa M.
Tun, Aung M.
Hoffmann, Marc S.
Narkhede, Mayur S.
Vaidya, Rakhee
Said, Rabih
Shapiro, Geoffrey I.
Costello, Brian A.
Ansell, Stephen M.
Nowakowski, Grzegorz S.
BLOOD, 2023, 142
[27] Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
Noriko Fukuhara
Dai Maruyama
Kiyohiko Hatake
Hirokazu Nagai
Shinichi Makita
Kenjiro Kamezaki
Toshiki Uchida
Shigeru Kusumoto
Junya Kuroda
Chisako Iriyama
Masamitsu Yanada
Norifumi Tsukamoto
Youko Suehiro
Hironobu Minami
Jose Garcia-Vargas
Barrett H. Childs
Masanobu Yasuda
Shigeo Masuda
Toshiaki Tsujino
Yui Terao
Kensei Tobinai
International Journal of Hematology, 2023, 117 : 100 - 109
[28] Phase 1 clinical study ofAtacicept in patients with relapsed and refractory B-cell lymphoma.
Ansell, Stephen
Witzig, Thomas E.
Novak, Anne
Inwards, David James
Porrata, Luis
Ythier, A.
Ferrande, L.
Nestorov, I.
DeVries, T.
Sievers, Eric
BLOOD, 2006, 108 (11) : 770A - 770A
[29] Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
Fukuhara, Noriko
Maruyama, Dai
Hatake, Kiyohiko
Nagai, Hirokazu
Makita, Shinichi
Kamezaki, Kenjiro
Uchida, Toshiki
Kusumoto, Shigeru
Kuroda, Junya
Iriyama, Chisako
Yanada, Masamitsu
Tsukamoto, Norifumi
Suehiro, Youko
Minami, Hironobu
Garcia-Vargas, Jose
Childs, Barrett H.
Yasuda, Masanobu
Masuda, Shigeo
Tsujino, Toshiaki
Terao, Yui
Tobinai, Kensei
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 100 - 109
[30] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K.
HAEMATOLOGICA, 2016, 101 : 317 - 317

← 1 2 3 4 5 →